Assessment of the Cylex ImmuKnow Cell Function Assay in Pediatric Heart Transplant Patients

Journal of Heart and Lung Transplantation

Volumn 28, Issue 1, 2009, Pages 26-31

  Rossano, Joseph W ^a   Denfield, Susan W ^a   Kim, Jeffrey J ^a   Price, Jack F ^a   Jefferies, John L ^a   Decker, Jamie A ^a   Smith, E O'Brian ^a   Clunie, Sarah K ^a   Towbin, Jeffrey A ^a   Dreyer, William J ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CELL ASSAY; CELL FUNCTION; CONTROLLED STUDY; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTIGENS, CD; BIOPSY; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; IMMUNOASSAY; INFECTION; ISOANTIBODIES; MALE; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 58149159560     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.10.001     Document Type: Article

References (29)

1. Ross M., Kouretas P., Gamberg P., et al. Ten- and 20-year survivors of pediatric orthotopic heart transplantation. J Heart Lung Transplant 25 (2006) 261-270
2. Morales D.L., Dreyer W.J., Denfield S.W., et al. Over two decades of pediatric heart transplantation: how has survival changed?. J Thorac Cardiovasc Surg 133 (2007) 632-639
3. Boucek M.M., Aurora P., Edwards L.B., et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report--2007. J Heart Lung Transplant 26 (2007) 796-807
4. Tjang Y.S., Stenlund H., Tenderich G., Hornik L., Bairaktaris A., and Korfer R. Risk factor analysis in pediatric heart transplantation. J Heart Lung Transplant 27 (2008) 408-415
5. Venkataramanan R., Shaw L.M., Sarkozi L., et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 41 (2001) 542-551
6. Barkholt L., Remberger M., Bodegard H., Ringden O., and Bottiger Y. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 40 (2007) 683-689
7. Mahalati K., Belitsky P., Sketris I., West K., and Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68 (1999) 55-62
8. Mahalati K., Belitsky P., West K., et al. A 3-hour postdose cyclosporine level during the first week after kidney transplantation predicts acute rejection and cyclosporine nephrotoxicity more accurately than trough levels. Transplant Proc 32 (2000) 786-787
9. Schubert S., Abdul-Khaliq H., Lehmkuhl H.B., et al. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients. J Heart Lung Transplant 25 (2006) 619-625
10. Delgado D.H., Rao V., Hamel J., Miriuka S., Cusimano R.J., and Ross H.J. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant 24 (2005) 1343-1346
11. Pape L., Ehrich J.H., and Offner G. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function. Clin Transplant 18 (2004) 576-579
12. Baraldo M., Isola M., Feruglio M.T., et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. Transplant Proc 37 (2005) 2240-2243
13. Dipchand A.I., Pietra B., McCrindle B.W., Rosebrook-Bicknell H.L., and Boucek M.M. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant 20 (2001) 1035-1043
14. Buell J.F., Gross T.G., Thomas M.J., et al. Malignancy in pediatric transplant recipients. Semin Pediatr Surg 15 (2006) 179-187
15. Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog Histochem Cytochem 39 (2004) 85-128
16. Lerut J.P. Avoiding steroids in solid organ transplantation. Transpl Int 16 (2003) 213-224
17. van den Berg F.A., Baken K.A., Vermeulen J.P., Gremmer E.R., van Steeg H., and van Loveren H. Use of the local lymph node assay in assessment of immune function. Toxicology 211 (2005) 107-114
18. Li B., Hartono C., Ding R., et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 344 (2001) 947-954
19. Muthukumar T., Dadhania D., Ding R., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353 (2005) 2342-2351
20. Horwitz P.A., Tsai E.J., Putt M.E., et al. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 110 (2004) 3815-3821
21. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17 (2003) 77-88
22. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
23. Gautam A., Morrissey P.E., Brem A.S., et al. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. Pediatr Transplant 10 (2006) 613-616
24. Hooper E., Hawkins D.M., Kowalski R.J., et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant 19 (2005) 834-839
25. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
26. Kim J.J., Dreyer W.J., O'Brian Smith E., et al. Leukocyte suppression is associated with improved clinical outcomes in children's status after orthotopic heart transplantation. J Heart Lung Transplant 25 (2006) 195-199
27. Gustafsson F., Barth D., Sheedy J., Nsouli M., Delgado D.H., and Ross H.J. Intralymphocytic cyclosporine exposure is not accurately predicted by C0 or C2 blood levels in everolimus treated patients. (abstract). J Heart Lung Transplant 27 (2008) S117-S118
28. Ballester M., Bordes R., Tazelaar H.D., et al. Evaluation of biopsy classification for rejection: relation to detection of myocardial damage by monoclonal antimyosin antibody imaging. J Am Coll Cardiol 31 (1998) 1357-1361
29. Marboe C.C., Billingham M., Eisen H., et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 24 (2005) S219-S226